FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2545351978> ?p ?o ?g. }

• W2545351978 abstract "Abstract Following a dose-escalation study performed in order to assess the maximally tolerated dose of high-dose mitoxantrone in a single injection (45mg/m2) combined with timed-sequential chemotherapy, a phase II trial (EMA-2000 regimen) was performed in high-risk AML. EMA-2000 regimen was effective (complete remission: 63%), but extra-hematologic toxicity appeared very high (53% of severe infections). In order to decrease toxicity, the same regimen was proposed between February 2004 and May 2006 followed by a single administration of Pegfilgrastim. Twenty-four patients entered the study and received mitoxantrone 45 mg/m2 on day 1 in combination with cytarabine (500 mg/m2 on days 1 to 3 and 8 to 10) and etoposide (200 mg/m2 on days 8 to 10) followed (after checking for the absence of blast in bone marrow aspirate performed at day 11) at day 12 by 6 mg of Pegfilgrastim administered by subcutaneous route. Overall, 15 patients (63%) achieved complete remission (CR) and 9 patients had resistant disease. Median time to achieve CR was 43 days. CR achievement was related to leukemia stage [50% (2/4 patients) in refractory AML and 65% (13/20 patients) in relapsed AML]. Median time to granulocyte recovery &gt; 0.5 × 109/l was 28 days. Median time to platelet recovery &gt; 50 × 109/l was 30 days. The predominant non-hematologic toxicity remained infections with 54% of septicemia and 62% of localized infections. Other severe extra-hematologic toxicity (WHO grade &gt; 2) were mucositis (50%), nausea and vomiting (33%), and diarrhea (17%). Pegfilgrastim was well tolerated. Nine of the 15 remitters received subsequent treatment consisting of maintenance chemotherapy courses in 3 patients, allogeneic stem cell transplantation (SCT) in 3 patients, and autologous SCT in 3 patients. Median DFS was 11.5 months with an estimated 2-year DFS rate of 37%. DFS was related to first CR duration (p = 0.01). Median OS was 12.5 months with a 2-year OS rate of 32%. Response to therapy, toxicity and survival were compared to those of our previous EMA-2000 regimen. Patient populations were matched on age, leukemia stage, performance status, and FAB subtypes. Outcome was similar regarding CR rate and extra-hematologic toxicity. Neutrophil and platelet recovery was only 2 days and 4 days shorter with the new regimen. However median DFS and OS, and 2-year survival estimate appeared better with the new regimen (11.5 months with 37% 2-year DFS vs 7.2 months with 16%; and 12.5 months with 32% vs 8.1 months with 18% respectively). This was confirmed whatever was the result of induction therapy. In patients achieving CR, median OS was 18.4 months with 61% 1-year OS vs 9.3 months with 36%, while in patients with no CR, median OS was 9.7 months with 44% 1-year OS vs 3.7 months with 8%. These results suggest a potential differentiating or immune-regulating effect of Pelfilgrastim. None of the patients with initial hyperleukocytosis (&gt; 10 × 109/l), who failed to achieve CR, recovered on a hyperleukocytosic mode. Biological explorations and a randomized study are warranted for confirming our results." @default.
• W2545351978 created "2016-11-04" @default.
• W2545351978 creator A5007908757 @default.
• W2545351978 creator A5024067286 @default.
• W2545351978 creator A5028508696 @default.
• W2545351978 creator A5052966035 @default.
• W2545351978 creator A5070792872 @default.
• W2545351978 creator A5072027146 @default.
• W2545351978 creator A5072721892 @default.
• W2545351978 creator A5087870886 @default.
• W2545351978 date "2006-11-16" @default.
• W2545351978 modified "2023-10-14" @default.
• W2545351978 title "Intensive Timed Sequential Chemotherapy Followed by a Single Pegfilgrastim (Neulasta) Administration in Patients with High-Risk Acute Myeloid Leukemia (AML): Preliminary Results of the EMA-2000/Neu Trial." @default.
• W2545351978 doi "https://doi.org/10.1182/blood.v108.11.4558.4558" @default.
• W2545351978 hasPublicationYear "2006" @default.
• W2545351978 type Work @default.
• W2545351978 sameAs 2545351978 @default.
• W2545351978 citedByCount "0" @default.
• W2545351978 crossrefType "journal-article" @default.
• W2545351978 hasAuthorship W2545351978A5007908757 @default.
• W2545351978 hasAuthorship W2545351978A5024067286 @default.
• W2545351978 hasAuthorship W2545351978A5028508696 @default.
• W2545351978 hasAuthorship W2545351978A5052966035 @default.
• W2545351978 hasAuthorship W2545351978A5070792872 @default.
• W2545351978 hasAuthorship W2545351978A5072027146 @default.
• W2545351978 hasAuthorship W2545351978A5072721892 @default.
• W2545351978 hasAuthorship W2545351978A5087870886 @default.
• W2545351978 hasConcept C126322002 @default.
• W2545351978 hasConcept C141071460 @default.
• W2545351978 hasConcept C2776694085 @default.
• W2545351978 hasConcept C2777063308 @default.
• W2545351978 hasConcept C2778041864 @default.
• W2545351978 hasConcept C2778119113 @default.
• W2545351978 hasConcept C2778336483 @default.
• W2545351978 hasConcept C2778496288 @default.
• W2545351978 hasConcept C2778658803 @default.
• W2545351978 hasConcept C2779171977 @default.
• W2545351978 hasConcept C2780580376 @default.
• W2545351978 hasConcept C2780923524 @default.
• W2545351978 hasConcept C2781413609 @default.
• W2545351978 hasConcept C71924100 @default.
• W2545351978 hasConcept C90924648 @default.
• W2545351978 hasConceptScore W2545351978C126322002 @default.
• W2545351978 hasConceptScore W2545351978C141071460 @default.
• W2545351978 hasConceptScore W2545351978C2776694085 @default.
• W2545351978 hasConceptScore W2545351978C2777063308 @default.
• W2545351978 hasConceptScore W2545351978C2778041864 @default.
• W2545351978 hasConceptScore W2545351978C2778119113 @default.
• W2545351978 hasConceptScore W2545351978C2778336483 @default.
• W2545351978 hasConceptScore W2545351978C2778496288 @default.
• W2545351978 hasConceptScore W2545351978C2778658803 @default.
• W2545351978 hasConceptScore W2545351978C2779171977 @default.
• W2545351978 hasConceptScore W2545351978C2780580376 @default.
• W2545351978 hasConceptScore W2545351978C2780923524 @default.
• W2545351978 hasConceptScore W2545351978C2781413609 @default.
• W2545351978 hasConceptScore W2545351978C71924100 @default.
• W2545351978 hasConceptScore W2545351978C90924648 @default.
• W2545351978 hasLocation W25453519781 @default.
• W2545351978 hasOpenAccess W2545351978 @default.
• W2545351978 hasPrimaryLocation W25453519781 @default.
• W2545351978 hasRelatedWork W136411592 @default.
• W2545351978 hasRelatedWork W2030146969 @default.
• W2545351978 hasRelatedWork W2033106246 @default.
• W2545351978 hasRelatedWork W2243134857 @default.
• W2545351978 hasRelatedWork W2386236634 @default.
• W2545351978 hasRelatedWork W2417640141 @default.
• W2545351978 hasRelatedWork W2423555368 @default.
• W2545351978 hasRelatedWork W2545351978 @default.
• W2545351978 hasRelatedWork W2561198757 @default.
• W2545351978 hasRelatedWork W2626793247 @default.
• W2545351978 isParatext "false" @default.
• W2545351978 isRetracted "false" @default.
• W2545351978 magId "2545351978" @default.
• W2545351978 workType "article" @default.